EXTH-33. RECEPTOR PHARMACOLOGY OF ONC201: THE FIRST BITOPIC DRD2 ANTAGONIST FOR CLINICAL NEURO-ONCOLOGY

ONC201 has exhibited durable tumor regressions in midline high grade glioma patients. G protein-coupled receptor (GPCR) dopamine receptor D2 (DRD2) is overexpressed in high grade gliomas, controls several oncogenic mechanisms, and its antagonism causes tumor cell apoptosis. Using bioinformatic and G...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro Oncol
Hauptverfasser: Benjamin Free, R, Cuoco, Caroline, Prabhu, Varun, Willette, Blair, Day, Marilyn, Anantharaman, Lakshmi, Sulli, Chidananda, Davidson, Edgar, Deacon, Sean, Rucker, Joseph, Charter, Neil, Doranz, Benjamin, Oster, Wolfgang, Stogniew, Martin, Robert Lane, J, Sibley, David, Allen, Joshua
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2019
Schlagworte:
Experimental Therapeutics
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847112/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.365
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge